DK1135158T3 - Forbedrede vacciner baseret på kimære immunglobulin-E-peptider - Google Patents

Forbedrede vacciner baseret på kimære immunglobulin-E-peptider

Info

Publication number
DK1135158T3
DK1135158T3 DK99963705T DK99963705T DK1135158T3 DK 1135158 T3 DK1135158 T3 DK 1135158T3 DK 99963705 T DK99963705 T DK 99963705T DK 99963705 T DK99963705 T DK 99963705T DK 1135158 T3 DK1135158 T3 DK 1135158T3
Authority
DK
Denmark
Prior art keywords
immunogenic polypeptides
methods
mammal
ige
nucleic acid
Prior art date
Application number
DK99963705T
Other languages
Danish (da)
English (en)
Inventor
Lars T Hellman
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Application granted granted Critical
Publication of DK1135158T3 publication Critical patent/DK1135158T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99963705T 1998-11-02 1999-10-21 Forbedrede vacciner baseret på kimære immunglobulin-E-peptider DK1135158T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
DK1135158T3 true DK1135158T3 (da) 2006-05-15

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963705T DK1135158T3 (da) 1998-11-02 1999-10-21 Forbedrede vacciner baseret på kimære immunglobulin-E-peptider

Country Status (17)

Country Link
US (3) US6913749B2 (https=)
EP (1) EP1135158B1 (https=)
JP (2) JP4205861B2 (https=)
KR (1) KR100559918B1 (https=)
AT (1) ATE314087T1 (https=)
AU (1) AU771889B2 (https=)
CA (1) CA2348756A1 (https=)
DE (1) DE69929240T2 (https=)
DK (1) DK1135158T3 (https=)
ES (1) ES2255325T3 (https=)
HU (1) HUP0105392A3 (https=)
IL (1) IL142582A0 (https=)
NO (1) NO20012135L (https=)
NZ (1) NZ511079A (https=)
PL (1) PL348611A1 (https=)
PT (1) PT1135158E (https=)
WO (1) WO2000025722A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2361635A3 (en) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
EP1330263A2 (en) * 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
ATE414540T1 (de) * 2002-09-05 2008-12-15 Resistentia Pharmaceuticals Ab Impfstoffe gegen allergien
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
KR101413844B1 (ko) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
EP4582442A3 (en) 2019-06-24 2025-10-29 Universität Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
WO1989006138A1 (en) 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
SG70982A1 (en) 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
EP0605410B1 (en) * 1990-05-25 1995-08-16 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
EP0811016A1 (en) 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
EP0839155B1 (en) * 1995-07-17 2004-10-13 Medivir UK Ltd CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR100584051B1 (ko) 1996-03-01 2006-05-30 노파르티스 아게 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
JP2000516808A (ja) 1996-08-05 2000-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｍｈｃ結合ペプチドオリゴマーおよび使用方法
TR199902562T2 (xx) 1997-04-15 2000-02-21 Farmaceutisk Laboratorium Ferring A/S De�i�tirilmi� TNF alfa molek�lleri
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
MXPA00007893A (es) 1998-02-11 2002-10-23 Maxygen Inc Direccion de vectores de vacunas geneticas.
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
TR200103046T2 (tr) 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP1330263A2 (en) 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
CN1541266A (zh) 2001-06-15 2004-10-27 唐诚公司 用于治疗过敏症及哮喘病的Fcε融合蛋白

Also Published As

Publication number Publication date
AU2008100A (en) 2000-05-22
EP1135158B1 (en) 2005-12-28
KR100559918B1 (ko) 2006-03-13
PL348611A1 (en) 2002-06-03
JP4205861B2 (ja) 2009-01-07
DE69929240D1 (de) 2006-02-02
EP1135158A2 (en) 2001-09-26
JP2002531064A (ja) 2002-09-24
US7459158B2 (en) 2008-12-02
JP4188353B2 (ja) 2008-11-26
HK1042844A1 (en) 2002-08-30
PT1135158E (pt) 2006-05-31
US20010038843A1 (en) 2001-11-08
WO2000025722A3 (en) 2000-10-12
CA2348756A1 (en) 2000-05-11
NO20012135D0 (no) 2001-04-30
ATE314087T1 (de) 2006-01-15
NO20012135L (no) 2001-06-25
JP2006068015A (ja) 2006-03-16
AU771889B2 (en) 2004-04-08
US6913749B2 (en) 2005-07-05
NZ511079A (en) 2003-08-29
HUP0105392A2 (hu) 2002-04-29
US20040076625A1 (en) 2004-04-22
ES2255325T3 (es) 2006-06-16
WO2000025722A2 (en) 2000-05-11
IL142582A0 (en) 2002-03-10
US20030031663A1 (en) 2003-02-13
KR20010089364A (ko) 2001-10-06
DE69929240T2 (de) 2006-08-31
HUP0105392A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
DK1135158T3 (da) Forbedrede vacciner baseret på kimære immunglobulin-E-peptider
NO346167B1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ATE148168T1 (de) Monoklonale antikörper
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
MX9801089A (es) Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna.
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2004050111A3 (en) Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
ATE421331T1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
Skea et al. Adhesion-mediated enhancement of the adjuvant activity of alum
NO20053363L (no) Malrettede enkle epitoper.
WO2004000238A3 (en) Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
Lou et al. Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine
Robert et al. Congenital toxoplasmosis: value of prenatal diagnosis and post-natal follow-up of newborns
EA200500943A1 (ru) Направленное действие на еденичные эпитопы
CR8389A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses